--- title: "Policy empowers the pharmaceutical industry to improve quality and upgrade. Zhendong Pharmacy strengthens its foundation and explores new multidimensional layouts to move forward steadily" type: "News" locale: "en" url: "https://longbridge.com/en/news/287499178.md" description: "Policy empowers the pharmaceutical industry to improve quality and upgrade. Zhendong Pharmacy strengthens its foundation and explores new multidimensional layouts to move forward steadily" datetime: "2026-05-25T06:11:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287499178.md) - [en](https://longbridge.com/en/news/287499178.md) - [zh-HK](https://longbridge.com/zh-HK/news/287499178.md) --- # Policy empowers the pharmaceutical industry to improve quality and upgrade. Zhendong Pharmacy strengthens its foundation and explores new multidimensional layouts to move forward steadily The current domestic pharmaceutical industry is entering a new stage of standardized and high-quality development. On May 15, the new "Regulations for the Implementation of the Drug Administration Law" officially came into effect. Coupled with the continuous deepening of the regular adjustment of the medical insurance catalog, the industry is accelerating the elimination of inefficient capacity and continuously transforming towards compliance operations, technological innovation, and quality upgrades. With the national policy dividends strongly promoting the revitalization of traditional Chinese medicine and continuously supporting the development of innovative drugs, high-quality pharmaceutical companies with a complete compliance system and strong product capabilities are continuously seizing the initiative in industry development and market opportunities. Against this industry backdrop, Zhendong Pharmacy (300158.SZ) precisely aligns with the policy orientation of the industry, deeply cultivates the core business of traditional Chinese medicine, continuously increases investment in innovative research and development, and lays out high-quality tracks in the health sector. With a standardized operating system and a differentiated product matrix, it continuously strengthens its core competitiveness and steadily promotes high-quality development of the enterprise. Currently, the regulation of the pharmaceutical industry is becoming increasingly refined and normalized, with policies continuously pressuring companies to strictly control product quality and standardize operational processes, thoroughly eliminating the chaotic phenomena of extensive development in the industry, and promoting the overall industry to advance towards high quality and standardization. Zhendong Pharmacy always regards compliance operations as the core bottom line of development, fully aligning with the new drug administration regulations, and building a comprehensive quality control system covering the entire chain from raw material procurement, intelligent production, finished product inspection, to warehousing and sales, achieving standardization and normalization of the entire drug production and operation process. The core business of traditional Chinese medicine serves as the fundamental advantage of the company. In line with the national strategy for the revitalization of traditional Chinese medicine, Zhendong Pharmacy focuses on the construction of the entire industry chain of authentic traditional Chinese medicine, relying on regional resource advantages, and deeply cultivating characteristic traditional Chinese medicinal materials such as forsythia and Lu-Dangshen, establishing a standardized planting and intelligent processing system, and promoting the upgrade of the traditional Chinese medicine industry towards standardization and modernization. On the product side, the company boasts several mature traditional Chinese medicine varieties, among which the Compound Sophora Flavescens Injection is a major achievement of the national major new drug creation project, with a solid clinical foundation and stable efficacy; main products such as Shuxue Ning Injection and Shengbai Granules, with safe and reliable quality, solidify market share and build a solid barrier for the core business of traditional Chinese medicine. Under the industrial trend of national support for new drug research and development, Zhendong Pharmacy has established a specialized research and development platform, focusing on high-prosperity sub-sectors such as dermatology, gynecology, digestion, and oncology, and improving the research and development team for innovative drugs and modified new drugs. Among them, the company's core product, Dafeixin Minoxidil Solution, is deeply engaged in the hair health field, maintaining a leading market position in the industry, and combined with hair growth tablets, forms an internal and external treatment plan that precisely matches the refined health consumption needs of the public. In terms of the implementation of the innovation pipeline, the NDA application for the vaginal Lactobacillus dual live bacteria capsule developed by the company's invested enterprise has been accepted, focusing on the female health sub-sector, aligning with the current national health consumption trend, and is expected to become a core incremental variety for the company in the future, further improving the layout of innovative products. The layout of the health sector opens up new growth space for the enterprise. Based on consolidating the pharmaceutical core business, Zhendong Pharmacy leverages its advantages in traditional Chinese medicine raw materials and research and development to smoothly enter the silver economy and national health care tracks, creating high-quality characteristic OTC anti-aging care products. The company relies on the advantages of authentic medicinal materials and professional clinical validation support to achieve a deep integration of traditional Chinese medicine resources and modern health needs, constructing a new pattern of coordinated industrial development and opening up a new growth curve for the enterprise The continuous release of industry policy dividends indicates a clear trend towards high-quality development in the pharmaceutical industry. In the future, Zhendong Pharmacy will continue to closely follow the national pharmaceutical industry policy direction, adhere to the dual main lines of innovative research and development and compliant operations, continuously optimize product structure, deepen the layout of the traditional Chinese medicine industry chain, accelerate the landing of innovative products, and leverage differentiated competitive advantages to seize industry development opportunities and steadily expand growth space ### Related Stocks - [300158.CN](https://longbridge.com/en/quote/300158.CN.md) ## Related News & Research - [China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical](https://longbridge.com/en/news/294273054.md) - [BUZZ-Sleep apnea pill developer Apnimed poised to jump in debut after upsized IPO](https://longbridge.com/en/news/294533308.md) - [07:00 ETRactigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy](https://longbridge.com/en/news/294502084.md) - [EnergyVision to take over DATS 24 retail power and gas supply business from Virya Energy](https://longbridge.com/en/news/294314716.md) - [CSPC says China NMPA accepts sirolimus albumin-bound injection filing, grants priority review](https://longbridge.com/en/news/293936243.md)